



SEMPERIT GROUP H1 2018/Q2 2018 INVESTOR PRESENTATION

Dr Martin Füllenbach, CEO

Frank Gumbinger, CFO

23 August 2018



Agenda

Business and transformation update (p. 3)

Operational highlights (p. 7)

Financial performance (p. 11)

Management agenda (p. 25)

Appendix (p. 28)



Business and transformation update (1/3)

Semperit Group

- Intensified restructuring efforts
- Reduction of complexity, including closure of production sites:
 - Sempertrans production site in France closed in 2017
 - Sempertrans production site in China to be closed in 2018
 - Two Semperform production sites in Germany to be merged in 2018
 - Semperflex production site in Italy under review
 - Total number of production sites down by 3 to 14 as of end of 2018
- > 600 initiatives support 10% EBITDA margin target by end of 2020, but still major challenges at Sempermed
- International trade and customs developments need to be monitored closely

Focus of restructuring and transformation process: Achieve target profitability throughout all segments by end of 2020. This will be a key feature for future portfolio discussions.



Business and transformation update (2/3)

Industrial Sector

Semperflex



- Customers place orders more cautiously (due to potential customs changes)
- Italian production site in Rovigo under review (currently 5 production sites in Semperflex)

Semperform




- Development of application innovations for new markets
- Closure of Dalheim site and integration into Hueckelhoven in progress (both in Germany)

Sempertrans



- Quality of order intake increases
- 2 non-profitable Sempertrans sites less (France closed, China in progress)






Business and transformation update (3/3)

Medical Sector

Sempermed



- Raw materials shortage resulted in lower production capacity and production inefficiencies in Malaysia
- Impairment of € 55m, mainly for fixed assets, driven by:
 - Declining business development caused by growing competition and price pressure, the limited availability and price increases of some input factors and inefficiencies in production
 - Mid-term planning in light of ongoing restructuring and transformation process as well as the observable uncertainties in the business development of Sempermed





Agenda

Business and transformation update (p. 3)

Operational highlights (p. 7)





Financial performance (p. 11)

Management agenda (p. 25)

Appendix (p. 28)



H1 2018: Strong operating development



Raw material


- Sideward trend for rubber prices 
- Prices for carbon black, wires and some other raw materials still increasing 
- Fierce competition for supply of some of our raw materials continues 

¹⁾ H1 2018 figures adjusted for negative one-off effect of € 55m from impairment of Sempermed (adj. for EBIT and EAT only) and € 4m (EBITDA) / € 8m (EBIT, EAT) from closure of Sempertrans site in China. H1 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from restructuring expenses in France (€ 7m) and valuation adjustment in IT (EUR 5m).





Overview Semperflex and Sempertrans


H1 2018 vs. H1 2017



- Growth dynamics is slightly slowing down
- Additional capacities from competitors will come on stream
- Hydraulic hoses: solid increase of volume as new capacities in Czech Republic available
- Encouraging level of profitability



- Improved market environment
- Volume and revenue decrease driven by change in product mix and partly by closure of site in France and low production levels in China in H1'2018
- Increasing lead times as clear indicator for market recovery
- Profitability improvements Q1'18 to Q2'18




¹⁾ H1 2018 adjusted for negative one-off effect from closure of China of € 4m.

²⁾ H1 2017 adjusted for negative one-off effect closure of France of € 7m.





Overview Semperform and Sempermed

H1 2018 vs. H1 2017



- Stable volume development
- Increasing costs for raw materials still a burden for profitability
- Business performance Q2'18 improved compared to Q1'18 and Q4'17



- Growing competition and price pressure led to decrease of sales volumes
- Fierce competition with regards to supply of specific raw materials
- Operational efficiency still not sufficient, availability of raw materials a burden for profitability
- Impairment loss of € 55m



¹⁾ H1 2017 adjusted for positive one-off effects from JV transaction of € 78m .



Agenda

Business and transformation update (p. 3)

Operational highlights (p. 7)

Financial performance (p. 11)

Management agenda (p. 25)

Appendix (p. 28)



H1 2018 Financials / Profitability Overview

in EUR m	H1 2018	H1 2017	Change	Change in EUR m
Revenue	448.5	461.6	-2.8%	-13.1
<i>EBITDA adjusted¹⁾</i>	32.7	22.5	+45.3%	10.2
<i>EBITDA margin adjusted</i>	7.3%	4.9%	+2.4 PP	–
EBITDA	28.9	97.3	-70.3%	-68.4
EBITDA margin	6.4%	21.1%	-14.7 PP	–
<i>EBIT adjusted¹⁾</i>	13.2	6.2	>100%	7.0
<i>EBIT margin adjusted</i>	2.9%	1.3%	+1.6 PP	–
EBIT	-49.8	54.3	–	-104.1
EBIT margin	-11.1%	11.8%	–	–
<i>Earnings after tax adjusted¹⁾</i>	-4.4	-7.9	-44.8%	+3.6
Earnings after tax	-67.4	21.2	–	-88.6
<i>Earnings per share (EPS) adj.²⁾, in EUR</i>	-0.21	-0.39	-44.8%	–
Earnings per share (EPS)²⁾, in EUR	-3.33	1.03	–	–


¹⁾ H1 2018 adjusted for negative one-off effect of € 55m from impairment of Sempermed (adj. for EBIT and EAT only) and € 4m (EBITDA) / € 8m (EBIT, EAT) from closure of Sempertrans site in China. H1 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from restructuring expenses in France (€ 7m) and valuation adjustment in IT (€ 4m).

²⁾ Attributable to the shareholders of Semperit AG Holding.



Revenue development H1 2018

in EUR m



Revenue development

- Semperflex: mainly higher volume translates into higher revenue
- Sempertrans: Revenue decrease driven by lower volume and product mix, also impacted by closure of site in France and low production levels in China in H1'2018
- Semperform: stable overall volume development
- Sempermed: Decrease of volume and revenue as a result of growing competition and price pressure

Revenue H1 2018 ►


121.5m	71.7m	98.2m	157.1m
--------	-------	-------	--------

¹⁾ Change of each segment / sector for H1 2018 vs H1 2017.




From reported to operating EBITDA / EBIT H1 2018

in EUR m





Operating EBITDA development H1 2018



	H1 2017	Semperfex	Sempertrans	Semperform	Sempermed	Corporate	H1 2018
Operating EBITDA H1 2017 ¹⁾	22.5m	22.2m	-1.8m	12.7m	1.7m	-12.3m	
Operating EBITDA H1 2018 ²⁾		28.7m	1.3m	11.8m	0.1m	-9.1m	32.7m
Operating EBITDA margin H1 2018		23.6%	1.8%	12.1%	0.1%	-	7.3%

¹⁾ H1 2017 adjusted for positive one-off effects from JV transaction of € 85m for Sempermed and negative one-off effects from restructuring expenses in France for Sempertrans (€ 7m) and valuation adjustment in IT for Corporate Center (€ 3m).

²⁾ H1 2018 adjusted for negative one-off effects of € 4m from closure of Sempertrans site in China.



Q2 2018 Financials / Profitability Overview

in EUR m	Q2 2018	Q2 2017	Change	Change in EUR m
Revenue	227.6	232.3	-2.0%	-4.7
<i>EBITDA adjusted¹⁾</i>	17.0	12.9	+31.4%	4.1
<i>EBITDA margin adjusted</i>	7.5%	5.6%	+1.9 PP	–
EBITDA	13.1	2.9	>100%	10.2
EBITDA margin	5.8%	1.2%	+4.6 PP	–
<i>EBIT adjusted¹⁾</i>	7.2	4.6	+55.1%	2.6
<i>EBIT margin adjusted</i>	3.2%	2.0%	+1.2 PP	–
EBIT	-55.8	-32.0	+74.1%	-23.8
EBIT margin	-24.5%	-13.8%	-10.7 PP	–
<i>Earnings after tax adjusted¹⁾</i>	-1.7	-6.1	>100%	+4.3
Earnings after tax	-64.8	-41.6	+55.7%	-23.2
<i>Earnings per share (EPS) adj.²⁾, in EUR</i>	-0.08	-0.30	-71.3%	–
Earnings per share (EPS)²⁾, in EUR	-3.19	-2.02	+57.8%	–


¹⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT only) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only). Q2 2017 adjusted for negative one-off effects from closure of Sempertrans site in France (€ 7m) and for impairment of Sempermed of € 26m (adj. for EBIT and EAT only).

²⁾ Attributable to the shareholders of Semperit AG Holding.



Revenue development Q2 2018

in EUR m



Revenue development

- Semperfex: mainly higher volume translates into higher revenue
- Sempertrans: Revenue decrease driven by lower volume and product mix, also impacted by closure of site in France and low production levels in China in H1'2018
- Semperform: stable overall volume development
- Sempermed: Decrease of volume and revenue as a result of growing competition and price pressure

Revenue Q2 2018 ►


62.8m	37.0m	50.7m	77.1m
-------	-------	-------	-------

¹⁾ Change of each segment / sector for Q2 2018 vs Q2 2017.




From reported to operating EBITDA / EBIT Q2 2018

in EUR m





Operating EBITDA development Q2 2018




Operating EBITDA Q2 2017 ¹⁾	12.9m	10.5m	-2.4m	7.8m	1.7m	-4.7m	
Operating EBITDA Q2 2018 ²⁾		14.9m	0.8m	7.3m	-1.3m	-4.7m	17.0m
Operating EBITDA margin Q2 2018		23.8%	2.1%	14.4%	-1.7%	-	7.5%

¹⁾ Q2 2017 adjusted for negative one-off effects from closure of Sempertrans site in France of € 7m.

²⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China of € 4m.



Operating EBITDA and EBITDA margin by quarter¹⁾



EBITDA development


- EBITDA in Q2 2018 again higher than in Q1 2018
- EBITDA margin of 7.5% well below target of ~10% by end of 2020
- All segments positive on EBITDA level (adj. where applicable)

¹⁾ Q2, Q3 and Q4 2017 adj. for restructuring expenses/ closure in France (€ 11m), valuation adjustment in IT (€ 3m), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge).
Q2 2018 adj. for closure of Sempertrans site in China (€ 4m).




Profitability overview


Industrial Sector




Semperflex



Semperform




Sempertrans



Medical Sector

Sempermed




■ EBITDA adj., in EURm
 — EBITDA margin adj.



CAPEX Overview

CAPEX per Segment


in EUR m





Working Capital Overview

Components of Working Capital in EUR m




¹⁾ Trade Working Capital in % of LTM revenues



Net debt significantly reduced

Balance sheet structure 30 June 2018

Balance sheet total: EUR 872 m



Financial profile as of 30 June 2018

- Cash and cash equivalents of € 201m
- Financial liabilities:
 - Corporate Schuldschein loan of € 272m
 - Liabilities to banks of € 8m
- Net debt of € 79m
 - down by € 82m since end of Dec. 2017
 - Net debt / EBITDA of 2.48x, compared to 1.61x as of end of Dec. 2017
- Hybrid capital: € 130m drawn as of end of March 2018
- Equity ratio of 39.4%, compared to 32.6% as of end of Dec. 2017



Agenda

State of restructuring (p. 3)

Operational highlights (p. 7)

Financial performance (p. 11)

Management agenda (p. 25)

Appendix (p. 28)



Management agenda 2018

Focus on SemperMOVE10 to reach 10% EBITDA margin by end of 2020 through the following initiatives:

Operations initiatives



- Increase output / Overall Equipment Effectiveness (OEE)
- Production footprint
- Inventory management
- Reduce waste and scrap
- Total cost of quality

Sales initiatives



- Volume growth (new markets, new regions)
- Customer benefits/value, price differentiation by region
- Brand leverage

Procurement, SG&A initiatives



- Sustainable customer/supplier relationship
- Optimise compound chemicals
- Backoffice and IT efficiency

Investments

- Overall Capex of EUR 80m for FY 2018
- whereof approx. 50% for Semperflex and mixing expansion

Financial impact

- Further significant one-off charges possible
- Outlook remains suspended for coming quarters

Portfolio adjustment and growth initiatives only after successful restructuring.



Contact and financial calendar

Investor Relations Semperit Group

Stefan Marin, Head of Investor Relations

+43 1 79777 - 210

www.semperitgroup.com/en/ir

Modecenterstrasse 22

1031 Vienna, Austria

Financial Calendar 2018

23.08.2018

Half-year financial report 2018

21.11.2018

Report on the first three quarters 2018

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete.

Statements referring to people are valid for both men and women.



Agenda

State of restructuring (p. 3)

Operational highlights (p. 7)

Financial performance (p. 11)

Management agenda (p. 25)

Appendix (p. 28)



Impairment Sempermed in Q2 2018

Overview impairment

- Impairment of € 55m, mainly for fixed assets, driven by:
 - Declining business development caused by growing competition and price pressure, the limited availability and price increases of some input factors and inefficiencies in production
 - Mid-term planning in light of ongoing restructuring and transformation process as well as the observable uncertainties in the business development of Sempermed

Effects of impairment

- € 55.2m impairment recognised in profit and loss statement
- Almost all of the total impairment is an impairment of tangible assets (property / plant / equipment) associated with the Sempermed segment
- Tangible assets of Sempermed segment were about € 110m and are now, as of end of June 2018, down to about € 55m




Investments at a glance

Investment Overview


- **Capex 2017** of € 75m, thereof maintenance € ~30m
- **Capex 2018** of € ~80m expected
- Thereof about 60% **for expansion**:
 - 45% for further Semperflex expansion Czech Rep.
 - 35% for further mixing expansion¹⁾ mainly in Poland
 - ▶ Both projects initiated in 2015 and since then gradually implemented
 - 20% for other segments

Capex and depreciation


in EUR m



Expected Total Capex split HY 2018



Expected Expansion Capex split HY 2018





¹⁾ Mixing is responsible for preparing compounds used by all industrial segments; plants in Austria, Czech Rep., Germany, Poland, China, India, Thailand (for Semperflex JV).



Overview price indices rubber

Price movements for raw materials¹⁾ became highly unpredictable





¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2016 = 100



Overview price indices carbon black / wire rod

Significant increase for raw materials¹⁾ used in industrial segments



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2016 = 100



Hybrid Capital Line with B & C

- **Overview**

- Contract between Semperit AG Holding and B & C Holding GmbH (100% subsidiary of B & C Industrieholding GmbH) signed on 12th Dec. 2017
Total volume of up to EUR 150m
- Can be drawn in up to three tranches until end of 2018
- Interest rate agreed amounts to 5.25%,
commitment fee (for unused part of the line) is set at 1.75%
- EUR 130m drawn in March 2018

- **Benefits for Semperit**

- Financial support for transformation process
- Strengthening of balance sheet

The core shareholder supports the transformation process
and emphasises its long-term commitment to Semperit.



Sectors and Group: Q2 2018 as reported

in EUR m	Industrial Sector			Medical Sector			Semperit Group ¹⁾		
	Q2 2018	Q2 2017	%	Q2 2018	Q2 2017	%	Q2 2018	Q2 2017	%
Revenue	150.5	140.1	+7.4%	77.1	92.2	-16.4%	227.6	232.3	-2.0%
EBITDA	19.1	9.2	>100%	-1.3	1.7	–	13.1	2.9	>100%
EBITDA margin	12.7%	6.6%	+6.1 PP	-1.7%	1.9%	–	5.8%	1.2%	+4.6 PP
Adj. EBITDA²⁾	23.0	15.9	+44.2%	-1.3	1.7	–	17.0	12.9	+31.4%
Adj. EBITDA margin²⁾	15.3%	11.4%	+3.9 PP	-1.7%	1.9%	–	7.5%	5.6%	+1.9 PP
EBIT	9.5	4.3	>100%	-60.3	-27.2	>100%	-55.8	-32.0	+0.7%
EBIT margin	6.3%	3.1%	+3.2 PP	-78.2%	-29.5%	-48.7 PP	-24.5%	-13.8%	-10.7 PP
Adj. EBIT²⁾	17.4	11.1	+57.4%	-5.1	-1.2	>100%	7.2	4.6	55.1%
Adj. EBIT margin²⁾	11.6%	7.9%	+3.7 PP	-6.6%	-1.3%	-5.3 PP	3.2%	2.0%	+1.2 PP
Earnings after tax	–	–	–	–	–	–	-64.8	-41.6	+55.7%
Adj. Earnings after tax²⁾	–	–	–	–	–	–	-1.7	-6.1	>100%
Earnings per share in EUR³⁾	–	–	–	–	–	–	-3.19	-2.02	+57.8%
Adj. Earnings per share in EUR	–	–	–	–	–	–	-0.08	-0.30	-71.3%
Investments	15.5	9.1	+69.7%	1.6	4.6	-65.0%	17.6	14.1	+25.0%
Employees	3,745	3,519	+6.4%	3,008	2,871	+4.8%	6,874	6,532	+5.2%

¹⁾ Including Corporate Center costs (Holding, supporting functions, special projects): EBITDA: € -4.7m in Q2 2018 (€ -8.0m in Q2 2017), EBIT € -5.1m (€ -9.1m).

²⁾ Q2 2018 figures adjusted for negative one-off effect of € 55m from impairment of Sempermed (adj. for EBIT and EAT only) and € 4m (EBITDA) / € 8m (EBIT, EAT) from closure of Sempertrans site in China.

Q2 2017 adjusted for negative one-off effects from closure of Sempertrans site in France (€ 7m) and for impairment of Sempermed of € 26m (adj. for EBIT and EAT only).

³⁾ Attributable to the shareholders of Semperit AG Holding.



Semperit Group per quarter as reported

Semperit Group (reported)													
in EUR m	FY 2015 ¹⁾	Q1 2016	Q2 2016	Q3 2016	Q4 2016	FY 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017	FY 2017	Q1 2018	Q2 2018
Revenue	914.7	219.5	219.2	208.9	204.8	852.4	229.3	232.3	208.4	204.2	874.2	220.9	227.6
EBITDA	96.2	26.7	26.1	19.4	5.7	77.9	94.4	2.9	0.5	2.4	100.2	15.8	13.1
EBITDA margin	10.5%	12.2%	11.9%	9.3%	2.8%	9.1%	41.2%	1.2%	0.2%	1.2%	11.5%	7.1%	5.8%
EBIT	66.7	18.6	17.6	10.4	-19.3	27.3	86.4	-32.0	-8.2	-8.5	37.6	6.0	-55.8
EBIT margin	7.3%	8.5%	8.0%	5.0%	-9.4%	3.2%	37.7%	-13.8%	-3.9%	-4.2%	4.3%	2.7%	-24.5%
Financial result	-8.0	-5.9	-4.1	-2.7	-7.2	-19.9	-8.00	-6.5	-6.1	-4.9	-25.5	-5.7	-1.0
Earnings after tax	46.4	10.1	7.7	5.5	-32.2	-8.8	62.8	-41.6	-16.4	-31.1	-26.3	-1.7	-64.8
Earnings per share in EUR²⁾	2.26	0.49	0.38	0.27	-1.57	-0.43	3.06	-2.02	-0.79	-1.49	-1.25	-0.09	-3.19

¹⁾ Values for 2015 restated

²⁾ Attributable to shareholders of Semperit AG Holding




Semperit Group adj. where applicable


Semperit Group adj. where applicable

in EUR m	FY 2015 ¹⁾	Q1 2016 adj. ²⁾	Q2 2016 adj. ²⁾	Q3 2016 adj. ²⁾	Q4 2016 adj. ²⁾	FY 2016 adj. ²⁾	Q1 2017 adj. ³⁾	Q2 2017 adj. ³⁾	Q3 2017 adj. ³⁾	Q4 2017 adj. ³⁾	FY 2017 adj. ³⁾	Q1 2018	Q2 2018 adj. ⁴⁾
Revenue	914.7	219.5	219.2	208.9	204.8	852.4	229.3	232.3	208.4	204.2	874.2	220.9	227.6
EBITDA	96.2	24.6	25.5	17.4	7.2	74.7	9.6	12.9	10.4	2.9	35.8	15.8	17.0
EBITDA margin	10.5%	11.2%	11.7%	8.3%	3.5%	8.8%	4.2%	5.6%	5.0%	1.4%	4.1%	7.1%	7.5%
EBIT	66.7	16.5	17.1	8.4	-0.9	41.1	1.6	4.6	1.7	-8.7	-0.8	6.0	7.2
EBIT margin	7.3%	7.5%	7.8%	4.0%	-0.4%	4.8%	0.7%	2.0%	0.8%	-4.3%	-0.1%	2.7%	3.2%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Values for 2015 restated ²⁾ Figures for 2016 without profit contribution from SSC and adj. in Q4 2016 for JV transaction. ³⁾ Q1 2017 adj. for positive one-off effects from JV transaction of € 85m. Figures for Q2, Q3 and Q4 2017 adj. for impairment at Sempermed (€ 26m adj. for EBIT only), restructuring expenses/closure in France (€ 11m) and valuation adjustment in IT (€ 4m), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ⁴⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT) and for impairment of Sempermed of € 55m (adj. for EBIT only).



Semperflex and Sempertrans (adj. where applicable)

Semperflex

	FY 2015 ¹⁾	Q1 2016 ²⁾	Q2 2016 ²⁾	Q3 2016 ²⁾	Q4 2016 ²⁾	FY 2016 ²⁾	Q1 2017	Q2 2017	Q3 2017 adj. ³⁾	Q4 2017	FY 2017 adj. ³⁾	Q1 2018	Q2 2018
in EUR m													
Revenue	203.4	47.8	48.8	43.4	44.9	184.9	53.5	53.2	46.8	52.5	206.1	58.8	62.8
EBITDA	46.1	11.8	12.5	8.8	10.3	43.4	11.7	10.5	8.7	10.5	41.4	13.7	14.9
EBITDA margin	22.7%	24.7%	25.7%	20.2%	22.9%	23.5%	21.8%	19.8%	18.6%	19.9%	20.1%	23.4%	23.8%
EBIT	38.2	9.7	10.5	6.7	8.4	35.3	9.6	8.6	6.8	7.8	32.7	11.1	12.3
EBIT margin	18.8%	20.4%	21.5%	15.5%	18.6%	19.1%	18.0%	16.1%	14.5%	14.8%	15.9%	18.9%	19.7%

Sempertrans

	FY 2015 ¹⁾	Q1 2016	Q2 2016	Q3 2016	Q4 2016	FY 2016	Q1 2017	Q2 2017 adj. ⁴⁾	Q3 2017 adj. ⁴⁾	Q4 2017 adj. ⁴⁾	FY 2017 adj. ⁴⁾	Q1 2018	Q2 2018 adj. ⁵⁾
in EUR m													
Revenue	164.9	42.6	38.9	32.7	34.1	148.4	41.3	36.8	35.7	32.1	146.0	34.6	37.0
EBITDA	23.2	5.8	5.7	3.0	1.4	15.9	0.6	-2.4	-1.4	-2.1	-5.3	0.5	0.8
EBITDA margin	14.0%	13.6%	14.5%	9.2%	4.1%	10.7%	1.4%	-6.4%	-3.9%	-6.6%	-3.6%	1.4%	2.1%
EBIT	19.9	4.8	4.7	2.1	0.5	12.1	-0.3	-3.3	-2.2	-3.1	-8.9	-0.4	-0.1
EBIT margin	12.1%	11.3%	12.1%	6.3%	1.5%	8.2%	-0.8%	-8.9%	-6.3%	-9.6%	-6.1%	-1.1%	-0.2%

¹⁾ Values for 2015 restated ²⁾ Values for 2016 restated, the business unit Sheeting was reclassified from segment Semperflex to segment Semperform

³⁾ Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge (€ 1m) ⁴⁾ Adj. for restructuring expenses/closing in France (€ 11m)

⁵⁾ Adj. for € 4m (EBITDA) / € 8m (EBIT) from closure of Sempertrans site in China.



Semperform and Sempermed (adj. where applicable)

Semperform

	FY 2015 ¹⁾	Q1 2016 ²⁾	Q2 2016 ²⁾	Q3 2016 ²⁾	Q4 2016 ²⁾	FY 2016 ²⁾	Q1 2017	Q2 2017	Q3 2017 adj. ⁵⁾	Q4 2017	FY 2017 adj. ⁵⁾	Q1 2018	Q2 2018
in EUR m													
Revenue	152.8	43.2	47.6	44.3	38.1	173.1	45.3	50.1	46.9	42.7	185.0	47.5	50.7
EBITDA	24.3	7.4	9.1	7.6	6.1	30.2	5.0	7.8	5.2	3.6	21.5	4.5	7.3
EBITDA margin	15.9%	17.2%	19.0%	17.3%	16.0%	17.4%	10.9%	15.5%	11.0%	8.5%	11.6%	9.6%	14.4%
EBIT	19.1	5.7	7.2	5.7	4.0	22.5	3.0	5.8	3.2	1.3	13.3	2.4	5.1
EBIT margin	12.5%	13.1%	15.2%	12.8%	10.4%	13.0%	6.6%	11.5%	6.8%	3.0%	7.2%	5.0%	10.1%

Sempermed

	FY 2015 ¹⁾	Q1 2016 adj. ³⁾	Q2 2016 adj. ³⁾	Q3 2016 adj. ³⁾	Q4 2016 adj. ³⁾	FY 2016 adj. ³⁾	Q1 2017 adj. ⁴⁾	Q2 2017 adj. ⁴⁾	Q3 2017 adj. ⁵⁾	Q4 2017	FY 2017 adj. ^{4) 5)}	Q1 2018	Q2 2018 adj. ⁶⁾
in EUR m													
Revenue	393.7	85.9	83.8	88.6	87.6	346.0	89.2	92.2	78.8	76.9	337.1	80.0	77.1
EBITDA	29.4	4.0	1.3	-0.1	-1.7	3.4	0.0	1.7	1.6	-1.5	1.8	1.4	-1.3
EBITDA margin	7.5%	4.6%	1.6%	-0.2%	-2.0%	1.0%	±0.0%	1.9%	2.0%	-2.0%	0.5%	1.8%	-1.7%
EBIT	17.2	0.8	-2.2	-4.1	-4.6	-10.1	-2.8	-1.2	-1.5	-6.6	-12.1	-2.2	-5.1
EBIT margin	4.4%	0.9%	-2.6%	-4.6%	-5.3%	-2.9%	-3.1%	-1.3%	-1.8%	-8.6%	-3.6%	-2.8%	-6.6%

¹⁾ Values for 2015 restated ²⁾ Values for 2016 restated, the business unit Sheeting was reclassified from segment Semperflex to segment Semperform

³⁾ Adj. for negative one-off effects in Q4 2016 and without profit contribution from SSC for FY 2016

⁴⁾ Q1 2017 Sempermed adj. for positive one-off effects from JV transaction of € 78m for EBITDA/EBIT; Q2 2017 adj. for impairment at Sempermed (€ 26m, EBIT only).

⁵⁾ Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge (€ 2m for Semperform, € 2m for Sempermed)

⁶⁾ Adj. for negative one-off effect of € 55m from impairment of Sempermed (adj. for EBIT only)



Sectors and Group: H1 2018 vs H1 2017

in EUR m	Industrial Sector			Medical Sector			Semperit Group ¹⁾		
	H1 2018	H1 2017	%	H1 2018	H1 2017	%	H1 2018	H1 2017	%
Revenue	291.4	280.3	+4.0%	157.1	181.4	-13.4%	448.5	461.6	-2.8%
EBITDA	37.9	26.4	+43.7%	0.1	79.8	-99.9%	28.9	97.3	-70.3%
<i>EBITDA margin</i>	13.0%	9.4%	+3.6 PP	0.1%	44.0%	-43.9 PP	6.4%	21.1%	-14.7 PP
<i>Adj. EBITDA²⁾</i>	41.8	33.1	+26.0%	0.1	1.7	-94.2%	32.7	22.5	45.3%
<i>Adj. EBITDA margin²⁾</i>	14.3%	11.8%	+2.5 PP	0.1%	0.9%	-0.9 PP	7.3%	4.9%	+2.4 PP
EBIT	22.6	16.6	+36.3%	-62.5	48.1	–	-49.8	54.3	–
<i>EBIT margin</i>	7.8%	5.9%	+1.9 PP	-39.8%	26.5%	–	11.8%	11.8%	–
<i>Adj. EBIT²⁾</i>	30.5	23.4	+30.4%	-7.3	-4.0	82.7%	13.2	6.2	>100%
<i>Adj. EBIT margin²⁾</i>	10.5%	8.3%	+2.1 PP	-4.6%	-2.2%	-2.4 PP	2.9%	1.3%	+1.6 PP
Earnings after tax	–	–	–	–	–	–	-67.4	21.2	–
<i>Adj. Earnings after tax²⁾</i>	–	–	–	–	–	–	-4.4	-7.9	-44.8%
Earnings per share in EUR	–	–	–	–	–	–	-3.33	1.03	–
<i>Adj. Earnings per share in EUR</i>	–	–	–	–	–	–	-0.21	-0.39	-44.8%
Investments	33.5	22.1	+51.5%	8.0	13.2	-39.0%	42.1	35.8	17.5%
Employees	3,745	3,519	+6.4%	3,008	2,871	4.8%	6,874	6,532	5.2%

¹⁾ Including Corporate Center costs (Holding, supporting functions, special projects): EBITDA: € -9.1m in H1 2018 (€ -8.9m in H1 2017), EBIT € -9.9m (€ -10.4m).

²⁾ H1 2018 adjusted for negative one-off effect of € 55m from impairment of Sempermed (adj. for EBIT, EAT only) and € 4m (EBITDA) / € 8m (EBIT, EAT) from closure of Sempertrans site in China. H1 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), restructuring expenses in France (€ 7m) and valuation adjustment in IT (€ 5m adj. for EBIT, EAT only).

³⁾ Attributable to the shareholders of Semperit AG Holding.



Key figures 2008-2017

Key performance figures

in EUR m		2008	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	Adj. 2016 ⁴⁾	Adj. 2017 ⁵⁾
Revenue	in EUR million	655.3	588.1	689.4	820.0	828.6	906.3	858.3	914.7	852.4	874.2
EBITDA	in EUR million	87.9	102.8	112.3	110.0	108.7	132.5	101.9	96.2	74.7	35.8
EBITDA margin	in %	13.4%	17.5%	16.3%	13.4%	13.1%	14.6%	11.9%	10.5%	8.80%	4.1%
EBIT	in EUR million	58.7	69.6	82.3	80.4	72.5	87.8	63.8	66.7	41.1	-0.8
EBIT margin	in %	9.0%	11.8%	11.9%	9.8%	8.8%	9.7%	7.4%	7.3%	4.80%	-0,1%
Earnings after tax	in EUR million	44.9	38.8	45.4	51.8	46.2	54.9	37.8	46.4	15.2	-43.9
Earnings per share (EPS) ²⁾ , in EUR	in EUR	1.83	1.89	2.21	2.52	2.25	2.65	1.85	2.26	0.74	-2.13
Gross cash flow	in EUR million	78.0	92.6	91.0	89.4	85.6	116.2	89.9	55.7		32.2
Return on equity	in %	12.9%	12.5%	12.9%	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%

Balance sheet key figures

in EUR m		2008	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016	2017
Balance sheet total	in EUR million	485.5	531.5	593.5	616.7	824.5	852.1	826.3	937.8	1,034.5	853.2
Equity ²⁾	in EUR million	291.9	310.6	351.1	379.4	406.2	411.5	443.8	363.3	329.3	278.5
Equity ratio	in %	60.1%	58.4%	59.2%	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%
Investments in tangible and intangible assets	in EUR million	27.6	22.7	52.5	45.1	41.2	49.7	67.4	71.8	65.1	74.5
Employees (at balance sheet date)	no.	7,064	6,649	7,019	8,025	9,577	10,276	6,888	7,053	6,974	6,838

¹⁾ Values for 2011 restated (see Annual Report 2012, Notes 2.18), values for 2010 not restated. ²⁾ Attributable to shareholders of Semperit AG Holding.


³⁾ Values for 2014 and 2015 restated. ⁴⁾ Figures for 2016 without profit contribution from SSC, impairment Sempermed and trade tax / levies in Brazil

⁵⁾ Figures for FY 2017 adjusted for positive one-off effects from JV transaction (€ 85m), impairment at Sempermed (€ 26m, only for EBIT, EAT), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge), expenses for restructuring / plant closure in France (€ 11m) and for valuation adjustment IT (€ 4m).



Shareholder Structure

Shareholder structure



- B & C Holding Österreich GmbH, Vienna, Austria
- FMR Co., Inc (Fidelity Management & Research Company)
- Free Float

- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C
- Fidelity Management and Research is an American multinational financial services corporation